ArticleClinical diabetes : a publication of the American Diabetes Association2017
How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
Article in Clinical diabetes : a publication of the American Diabetes Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Efficacy and Safety of Biosimilar Ranibizumab (OPTIMABClinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.The British journal of ophthalmology · 2023Trial
- A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with LucentisIndian journal of ophthalmology · 2022Trial
- Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications.AAPS PharmSciTech · 2025Review
- National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond.BMJ global health · 2024Article
- The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.Journal of diabetes science and technology · 2023Review
- An Institutional Guide for Formulary Decisions of Biosimilars.Hospital pharmacy · 2023Review
- MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.